Replies to post #11790 on Dendreon Corp fka DNDNQ

[anon13333]

First, this the opening bid to put BP on notice.

This is just for Provenge and other certain assets.

Pursuant to the terms of the agreement, Valeant will acquire the world-wide rights to Dendreon's PROVENGE(R) (sipuleucel-T) product and certain other Dendreon assets.

What about other assets (e.g. the current phase III trial candidate) and other assets? They are worth something.

Also,

From PR:
Valeant will acquire the world-wide rights to Dendreon's PROVENGE® (sipuleucel-T) product and certain other Dendreon assets.

From docket 282:
Total Assets: $ 342,783 is not part of the deal.

VRX offer is 342M+296M=638M.

Anything more belong to shareholder.

Check the document and bring in your thoughts.

[was GoldenDD]

In any auction the average sells tends to be x3 to five times the minimum bid price. so my guess 900 mill to 1.5 billion will be the final price imo

[ATCrunch]

I believe nobody will let valeant steal this cheap. Like they said, they want it "cheap" and it supports there idea of " fast growth, etc" they want to enter the market cheap but I think other players have other ideas. A company that takes over should be able to cut cost and make them profitable. Lets say 350 rev and 50 m profit next year under a takeover with current model. 1 billion bid is only 20 price to earnings with that forecast. Then they have intellectual property which might add more value. I can get to that multiple pretty easy.